PPARδ agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
==== Intramuscular or subcutaneous ==== Naloxone can also be administered via intramuscular or subcutaneous injection. The onset of naloxone provided through this route is 2 to 5 minutes with a duration of around 30–120min. Naloxone administered intramuscularly are provided through pre-filled syringes, vials, and auto-injector. A hand-held auto-injector is pocket-sized and can be used in non-medical settings such as in the home. It is designed for use by laypersons, including family members and caregivers of opioid users at risk for an opioid emergency, such as an overdose. According to the FDA's National Drug Code Directory, a generic version of the auto-injector began to be marketed at the end of 2019.
== Deaths == 1 January – Sally Oppenheim-Barnes, Baroness Oppenheim-Barnes, 96, British politician, minister of state for consumer affairs (1979–1982), MP (1970–1987), and member of the House of Lords (1989–2019). 4 January – Jenny Randerson, Baroness Randerson, 76, Welsh politician and peer, acting Deputy First Minister of Wales (2001–2002) and member of the House of Lords (since 2011). 24 January – Joan Hanham, Baroness Hanham, 85, British politician, member of the House of Lords (1999–2020) and leader of the Kensington and Chelsea Council (1989–2000). 1 February – John Montagu, 11th Earl of Sandwich, 81, British aristocrat, businessman and politician, member of the House of Lords (1995–2024). 7 February – Dafydd Elis-Thomas, Baron Elis-Thomas, 78, Welsh politician, llywydd of the Senedd (1999–2011), MP (1974–1992) and member of the House of Lords (since 1992). 16 February – Barry Panter, politician (Mayor of Newcastle-under-Lyme), car crash. (death reported on this date) 19 February – Joe Haines, 97, British journalist and public servant, Downing Street press secretary (1969–1970, 1974–1976). 27 March – Christina McKelvie, 57, Scottish politician, MSP (since 2007), minister for culture (2023–2024) and drugs and alcohol policy (since 2024), breast cancer. 30 March – Stanley Kalms, Baron Kalms, 93, British businessman, chairman of Currys, and life peer, member of the House of Lords (2004–2024). 31 March – Janric Craig, 3rd Viscount Craigavon, 80, British hereditary peer and member of the House of Lords (since 1974) 23 April – Peter Taaffe, 83, British Marxist militant.
=== Russia-Ukraine conflict === Following Russia's invasion of Ukraine in 2022, Teva Pharmaceuticals faced criticism for continuing its operations in Russia despite international sanctions. While the company committed to stopping new investments, its focus on ensuring an uninterrupted supply of medicines has raised ethical concerns, with critics arguing that Teva's presence weakens the impact of sanctions aimed at pressuring Russia economically.
=== Drug and toxin metabolism === Chemicals contained in cruciferous vegetables induce the expression of the liver enzyme CYP1A2. Alliaceous and cruciferous vegetable consumption may induce glutathione S-transferases, uridine diphosphate-glucuronosyl transferases, and quinone reductases all of which are potentially involved in detoxification of carcinogens such as aflatoxin. High consumption of cruciferous vegetables has potential risk from allergies, interference with drugs such as warfarin, and genotoxicity.
Sources: en.wikipedia.org
== Toxicity == SRTX-b and SRTX-a are highly lethal and cause cardiac arrest and death in mice within minutes of intravenous administration, LD50 for mice was detected for about 0.015 mg/kg body weight and LD50 0.3 mg/kg in case of SRTX-c.
Introduced in the 1950s, the population of Nile perch in Lake Victoria has been targeted for its maw since the mid-2010s in Uganda, Kenya and Tanzania. Originally, skiff owners contract fishermen to fish for perch; the owners pay the fishermen, retain the fish and sell the maws to fish maw export companies. In 2018, the Government of Uganda introduced a law where the fish maw could not be removed until resale to a fish processing plant; official production of fish maw dropped sharply, possibly due to under-reporting from smuggling. In 2021, the government introduced a 7-percent export tariff on fish maw, in anticipation of a Chinese trade deal; the September 2024 Forum on China–Africa Cooperation eliminated the tariffs.
==== Dementia ==== Several studies have drawn an association between long-term benzodiazepine use and neurodegenerative disease, particularly Alzheimer's disease. It has been determined that long-term use of benzodiazepines is associated with increased dementia risk, even after controlling for protopathic bias. In contrast, a clinical study using florbetapir PET-CT and MRI to compute beta-amyloid load and hippocampal volume, respectively, found benzodiazepines to be associated with decreased beta-amyloid load and reduced hippocampal atrophy in a cohort of older nondemented adults with isolated/light cognitive impairments. Unlike previous imaging studies limited to MRI techniques, the utilization of a dual PET CT scanner to track the binding of the radioligand florbetapir to beta-amyloid provides stronger neuroimaging data with respect to alzheimer's related pathophysiology. Indeed, Avid's florbetapir PET technique has received FDA approval for diagnosing alzheimer's disease. Drug Approval Package Archived 10 June 2025 at the Wayback Machine However, there is still no causal evidence regarding how benzodiazepines affect the risk of alzheimer's disease or dementia.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.